Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
136 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016, provides an overview of the Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline landscape. Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred or decreased central close-up and distance vision, blind spots, micropsia and straight lines look distorted. Predisposing factors include age and family history. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 2, 14, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Dry (Atrophic) Macular Degeneration. Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Dry (Atrophic) Macular Degeneration Overview 11 Therapeutics Development 12 Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview 12 Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis 13 Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies 14 Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 16 Dry (Atrophic) Macular Degeneration - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Dry (Atrophic) Macular Degeneration - Products under Development by Companies 21 Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes 23 Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development 24 Aciont Inc. 24 Alimera Sciences, Inc. 25 Allergan Plc 26 Apellis Pharmaceuticals Inc 27 Astellas Pharma Inc. 28 Benitec Biopharma Limited 29 Biophytis SAS 30 Catalyst Biosciences, Inc. 31 Cell Cure Neurosciences, Ltd. 32 Charlesson LLC. 33 Foamix Pharmaceuticals Ltd. 34 Genentech Inc 35 GenSight Biologics S.A. 36 GlaxoSmithKline Plc 37 Icon Bioscience, Inc. 38 Inception Sciences, Inc. 39 Johnson & Johnson 40 Kodiak Sciences Inc. 41 MacuCLEAR Inc 42 MeiraGTx Limited 43 Novartis AG 44 Ophthotech Corp. 45 Orphagen Pharmaceuticals, Inc. 46 pSivida Corp. 47 Samumed LLC 48 Sucampo Pharmaceuticals, Inc. 49 Sun Pharma Advanced Research Co Ltd 50 Dry (Atrophic) Macular Degeneration - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 54 Assessment by Route of Administration 56 Assessment by Molecule Type 58 Drug Profiles 60 A-005 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 APL-2 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 avacincaptad pegol sodium - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 BBAMD-231 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 BIO-201 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 brimonidine tartrate implant - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 CLG-561 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 CLT-005 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 CNTO-2476 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Drug for Age Related Macular Degeneration - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 EG-30 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 FMX-103 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Gene Therapy for Ocular Diseases - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 GS-030 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 GSK-933776 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 ICR-14967 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 KSI-401 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 lampalizumab - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 MA09-hRPE - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 MC-1101 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 methotrexate - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 OCU-100 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 ONL-1204 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 OpRegen - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 OpRegen Plus - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 RC-1 Alpha - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 RST-001 - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 Small Molecule for Dry AMD and Wet AMD - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 Small Molecules for AMD - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 Small Molecules for Dry AMD - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 tesidolumab - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 unoprostone isopropyl - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 VM-100 - Drug Profile 120 Product Description 120 Mechanism Of Action 120 R&D Progress 120 Dry (Atrophic) Macular Degeneration - Dormant Projects 121 Dry (Atrophic) Macular Degeneration - Discontinued Products 124 Dry (Atrophic) Macular Degeneration - Product Development Milestones 125 Featured News & Press Releases 125 Aug 30, 2016: RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics 125 May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences 125 Apr 12, 2016: BIOPHYTIS to Present Pre-Clinical Data on BIO 201 at Upcoming Scientific Conference 126 Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia 126 Oct 01, 2013: Roche to present data on Lampalizumab at investor event 127 Aug 27, 2013: Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 127 Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 128 May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 129 Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy 129 Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy 130 Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells 131 Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference 132 Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone 132 Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells 133 Aug 02, 2012: ACT Announces First Dry Age-Related Macular Degeneration Patient Treated With Higher Dosage Of Embryonic Stem Cell-Derived RPE Cells 134 Appendix 135 Methodology 135 Coverage 135 Secondary Research 135 Primary Research 135 Expert Panel Validation 135 Contact Us 135 Disclaimer 136
List of Tables
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016 12 Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Number of Products under Development by Companies, H2 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Clinical Stage Development, H2 2016 18 Comparative Analysis by Early Stage Development, H2 2016 19 Comparative Analysis by Unknown Stage Development, H2 2016 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H2 2016 23 Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H2 2016 24 Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2016 25 Dry (Atrophic) Macular Degeneration - Pipeline by Allergan Plc, H2 2016 26 Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 27 Dry (Atrophic) Macular Degeneration - Pipeline by Astellas Pharma Inc., H2 2016 28 Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016 29 Dry (Atrophic) Macular Degeneration - Pipeline by Biophytis SAS, H2 2016 30 Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2016 31 Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2016 32 Dry (Atrophic) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016 33 Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 34 Dry (Atrophic) Macular Degeneration - Pipeline by Genentech Inc, H2 2016 35 Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics S.A., H2 2016 36 Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2016 37 Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016 38 Dry (Atrophic) Macular Degeneration - Pipeline by Inception Sciences, Inc., H2 2016 39 Dry (Atrophic) Macular Degeneration - Pipeline by Johnson & Johnson, H2 2016 40 Dry (Atrophic) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016 41 Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR Inc, H2 2016 42 Dry (Atrophic) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016 43 Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H2 2016 44 Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016 45 Dry (Atrophic) Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 46 Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2016 47 Dry (Atrophic) Macular Degeneration - Pipeline by Samumed LLC, H2 2016 48 Dry (Atrophic) Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 49 Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016 50 Assessment by Monotherapy Products, H2 2016 51 Number of Products by Stage and Target, H2 2016 53 Number of Products by Stage and Mechanism of Action, H2 2016 55 Number of Products by Stage and Route of Administration, H2 2016 57 Number of Products by Stage and Molecule Type, H2 2016 59 Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2016 121 Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H2 2016 122 Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..2), H2 2016 123 Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2016 124
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.